{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T19:35:29Z","timestamp":1772998529214,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Internal Funds KU Leuven","award":["C24\/18\/097"],"award-info":[{"award-number":["C24\/18\/097"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Neuronal hyperexcitability has been proposed to play a key role in Alzheimer\u2019s disease (AD). Understanding the relation between this enhanced excitability and AD pathology could provide a window for therapeutic interventions. However epileptiform activity is often subclinical, hidden on scalp EEG and very challenging to assess with current diagnostic modalities.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A woman in her sixties presented with acute confusion. Despite a normal scalp electroencephalogram (EEG), magnetic resonance imaging (MRI) showed cytotoxic edema of the right mesial temporal lobe and hippocampal hypermetabolism was present on ([<jats:sup>18<\/jats:sup>F]-fluoro-2-deoxyglucose positron emission tomography (PET). Bilateral foramen ovale (FO) electrodes were placed to directly record mesial temporal activity and revealed continuous mesial temporal epileptic activity, while scalp EEG remained normal. After recovery, a new diagnosis of AD was established on cerebrospinal fluid. The lateralization of the epileptiform activity was congruent with the predominant side of tau pathology in the mesial temporal cortex on <jats:sup>18<\/jats:sup>F-MK6240 PET. On follow-up MRI, two and five months later, the right hippocampus became atrophic.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This case highlights the significant role of neuronal hyperexcitability in early AD pathogenesis and how shared mechanisms between AD and epilepsy can complicate clinical management.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12883-024-03979-4","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T09:01:42Z","timestamp":1734512502000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A case report about focal status epilepticus as first presentation in Alzheimer\u2019s disease: finding the culprit"],"prefix":"10.1186","volume":"24","author":[{"given":"Astrid","family":"Devulder","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Greet","family":"Vanderlinden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evy","family":"Cleeren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerie","family":"Goovaerts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom","family":"Theys","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koen","family":"Van Laere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wim","family":"Van Paesschen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,18]]},"reference":[{"key":"3979_CR1","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF00308809","volume":"82","author":"H Braak","year":"1991","unstructured":"Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239\u201359.","journal-title":"Acta Neuropathol"},{"key":"3979_CR2","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1093\/brain\/aww027","volume":"139","author":"R Ossenkoppele","year":"2016","unstructured":"Ossenkoppele R, Schonhaut DR, Scholl M, et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer\u2019s disease. Brain. 2016;139:1551\u201367.","journal-title":"Brain"},{"key":"3979_CR3","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1038\/nn.4328","volume":"19","author":"JW Wu","year":"2016","unstructured":"Wu JW, Hussaini SA, Bastille IM, et al. Neuronal activity enhances tau propagation and tau pathology in vivo. Nat Neurosci. 2016;19:1085\u201392.","journal-title":"Nat Neurosci"},{"key":"3979_CR4","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.nbd.2018.07.003","volume":"118","author":"MK Schultz Jr","year":"2018","unstructured":"Schultz MK Jr., Gentzel R, Usenovic M, et al. Pharmacogenetic neuronal stimulation increases human tau pathology and trans-synaptic spread of tau to distal brain regions in mice. Neurobiol Dis. 2018;118:161\u201376.","journal-title":"Neurobiol Dis"},{"key":"3979_CR5","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/s41467-019-14159-1","volume":"11","author":"N Franzmeier","year":"2020","unstructured":"Franzmeier N, Neitzel J, Rubinski A, et al. Functional brain architecture is associated with the rate of tau accumulation in Alzheimer\u2019s disease. Nat Commun. 2020;11:347.","journal-title":"Nat Commun"},{"key":"3979_CR6","doi-asserted-by":"crossref","unstructured":"Vogel JW, Iturria-Medina Y, Strandberg OT et al. Spread of pathological tau proteins through communicating neurons in human Alzheimer\u2019s disease. Nat Commun 2020; 11.","DOI":"10.1101\/555821"},{"key":"3979_CR7","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1146\/annurev-neuro-080317-061725","volume":"41","author":"B Zott","year":"2018","unstructured":"Zott B, Busche MA, Sperling RA, Konnerth A. What happens with the Circuit in Alzheimer\u2019s Disease in mice and humans? Annu Rev Neurosci. 2018;41:277\u201397.","journal-title":"Annu Rev Neurosci"},{"key":"3979_CR8","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1002\/ana.24794","volume":"80","author":"KA Vossel","year":"2016","unstructured":"Vossel KA, Ranasinghe KG, Beagle AJ, et al. Incidence and impact of subclinical epileptiform activity in Alzheimer\u2019s disease. Ann Neurol. 2016;80:858\u201370.","journal-title":"Ann Neurol"},{"key":"3979_CR9","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1001\/jamaneurol.2021.3310","volume":"78","author":"KA Vossel","year":"2021","unstructured":"Vossel KA, Ranasinghe KG, Beagle AJ, et al. Effect of Levetiracetam on Cognition in patients with Alzheimer Disease with and without epileptiform activity: a Randomized Clinical Trial. JAMA Neurol. 2021;78:1345\u201354.","journal-title":"JAMA Neurol"},{"key":"3979_CR10","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/nm.4330","volume":"23","author":"AD Lam","year":"2017","unstructured":"Lam AD, Deck G, Goldman A, et al. Silent hippocampal seizures and spikes identified by foramen ovale electrodes in Alzheimer\u2019s disease. Nat Med. 2017;23:678\u201380.","journal-title":"Nat Med"},{"key":"3979_CR11","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.eplepsyres.2013.03.006","volume":"105","author":"F Siclari","year":"2013","unstructured":"Siclari F, Prior JO, Rossetti AO. Ictal cerebral positron emission tomography (PET) in focal status epilepticus. Epilepsy Res. 2013;105:356\u201361.","journal-title":"Epilepsy Res"},{"key":"3979_CR12","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1136\/jnnp.55.10.967","volume":"55","author":"P Scheltens","year":"1992","unstructured":"Scheltens P, Leys D, Barkhof F, et al. Atrophy of medial temporal lobes on MRI in probable Alzheimer\u2019s disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry. 1992;55:967\u201372.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3979_CR13","doi-asserted-by":"crossref","unstructured":"Devulder A, Vanderlinden G, Van Langenhoven L et al. Epileptic activity on foramen ovale electrodes is associated with sleep and tau pathology in Alzheimer\u2019s disease. Brain. 2024.","DOI":"10.1093\/brain\/awae231"},{"key":"3979_CR14","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1097\/00002093-200010000-00008","volume":"14","author":"AL Rabinowicz","year":"2000","unstructured":"Rabinowicz AL, Starkstein SE, Leiguarda RC, Coleman AE. Transient epileptic amnesia in dementia: a treatable unrecognized cause of episodic amnestic wandering. Alzheimer Dis Assoc Disord. 2000;14:231\u20133.","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"3979_CR15","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.3233\/JAD-221197","volume":"94","author":"G Hautecloque-Raysz","year":"2023","unstructured":"Hautecloque-Raysz G, Sellal F, Bousiges O, et al. Epileptic Prodromal Alzheimer\u2019s Disease treated with antiseizure medications: medium-term outcome of seizures and cognition. J Alzheimers Dis. 2023;94:1057\u201374.","journal-title":"J Alzheimers Dis"},{"key":"3979_CR16","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/s41591-021-01309-6","volume":"27","author":"JW Vogel","year":"2021","unstructured":"Vogel JW, Young AL, Oxtoby NP, et al. Four distinct trajectories of tau deposition identified in Alzheimer\u2019s disease. Nat Med. 2021;27:871\u201381.","journal-title":"Nat Med"},{"key":"3979_CR17","unstructured":"Young CB, Winer JR, Younes K et al. Divergent cortical tau Positron Emission tomography patterns among patients with preclinical Alzheimer Disease. JAMA Neurol 2022."},{"key":"3979_CR18","doi-asserted-by":"publisher","first-page":"103416","DOI":"10.1016\/j.nicl.2023.103416","volume":"38","author":"J Lu","year":"2023","unstructured":"Lu J, Zhang Z, Wu P, et al. The heterogeneity of asymmetric tau distribution is associated with an early age at onset and poor prognosis in Alzheimer\u2019s disease. Neuroimage Clin. 2023;38:103416.","journal-title":"Neuroimage Clin"},{"key":"3979_CR19","doi-asserted-by":"publisher","first-page":"e209920","DOI":"10.1212\/WNL.0000000000209920","volume":"103","author":"AD Lam","year":"2024","unstructured":"Lam AD, Thibault EG, Mayblyum DV, et al. Association of Seizure Foci and Location of tau and Amyloid Deposition and brain atrophy in patients with Alzheimer Disease and seizures. Neurology. 2024;103:e209920.","journal-title":"Neurology"},{"key":"3979_CR20","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1093\/brain\/aww187","volume":"139","author":"XY Tai","year":"2016","unstructured":"Tai XY, Koepp M, Duncan JS, et al. Hyperphosphorylated tau in patients with refractory epilepsy correlates with cognitive decline: a study of temporal lobe resections. Brain. 2016;139:2441\u201355.","journal-title":"Brain"},{"key":"3979_CR21","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1002\/alz.12943","volume":"19","author":"I Zawar","year":"2023","unstructured":"Zawar I, Kapur J. Does Alzheimer\u2019s disease with mesial temporal lobe epilepsy represent a distinct disease subtype? Alzheimers Dement. 2023;19:2697\u2013706.","journal-title":"Alzheimers Dement"},{"key":"3979_CR22","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/s41582-021-00505-9","volume":"17","author":"M Romoli","year":"2021","unstructured":"Romoli M, Sen A, Parnetti L, et al. Amyloid-\u03b2: a potential link between epilepsy and cognitive decline. Nat Rev Neurol. 2021;17:469\u201385.","journal-title":"Nat Rev Neurol"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-024-03979-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-024-03979-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-024-03979-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T09:07:44Z","timestamp":1734512864000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-024-03979-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,18]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3979"],"URL":"https:\/\/doi.org\/10.1186\/s12883-024-03979-4","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,18]]},"assertion":[{"value":"16 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained for all procedures from the participant and caregiver. The study was approved by the Ethical Committee of University Hospitals Leuven (clinical.trials.gov NCT03617497).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Patient gave written informed consent for publication of the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"K.V.L. has contract research through Leuven Research and Development with BMS, Cerevel and Janssen Pharmaceuticals and is advisory board member for <sup>18<\/sup>F-MK6240 for Cerveau-Enigma. W.V.P. has grant for Toegepast Biomedisch Onderzoeks-Fonds voor Wetenschappelijk Onderzoek (FWO-TBM) (T000423N) and receives consulting fees from Angeline Pharma, UCB Pharma and Byteflies. The other authors have nothing to report.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"478"}}